Bluejay Diagnostics completes 1-for-4 reverse stock split effective November 3, 2026
Bluejay Diagnostics (Nasdaq: BJDX) completed a 1-for-4 reverse stock split effective November 3, 2026. The Board selected the ratio from a range of 1-for-2 to 1-for-20 that stockholders approved in June, and the cut reduced common shares outstanding from about 4,468,051 to about 1,117,013. The par value and voting rights are unchanged, and holders of fractional shares will receive cash, but the press release describes a three-for-one combination while the 8-K describes four-for-one, so the terms should be confirmed with the transfer agent.
Key points
- Split effective 12:01 a.m. Eastern Time on November 3, 2026; BJDX began trading post-split on the Nasdaq Capital Market under new CUSIP 095633707.
- Common shares outstanding fell from about 4,468,051 to about 1,117,013; prefunded warrant shares fell from 222,581 to 55,646 (press release says 55,645).
- Stockholders approved the split at the June 9, 2026 annual meeting; the Board chose 1-for-4 and the certificate was filed October 30, 2026.
- Fractional-share holders receive cash based on the recent average closing price; the press release describes every three shares combining into one, conflicting with the 8-K's four-for-one terms.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.